Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

135 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate breast reconstruction with implants using biological mesh (Strattice™) in the setting of breast cancer treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction

NCT05316324

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE3

Acellular Dermal Matrix in Breast Reconstruction

NCT02835781

Breast Cancer

COMPLETED

Breast Reconstruction Outcomes With and Without StratticE

NCT02608593

Breast Neoplasms

COMPLETED

Evaluation of a Human Acellular Dermal Matrix in Post Mastectomy Reconstruction

NCT02263261

Mastectomy Breast Reconstruction

COMPLETED NA

Immediate Breast Reconstruction With Acellular Dermal Matrix

NCT04209010

Breast Cancer Breast Carcinoma in Situ Mammaplasty +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES: To evaluate the outcome of immediate breast reconstruction with Acellular Dermal Matrix (Strattice™), measuring safety, effectiveness, and costs. The primary outcome measure is number of unplanned surgical procedures.

STUDY DESIGN: A prospective randomized multicenter trial. One hundred and twenty patients with breast cancer will be enrolled into the study. Study duration will be two years from time of primary cancer surgery.

TRIAL DESIGN This is a randomized controlled multicenter trial, comparing IBR without (group A) and with (group B) the use of ADM. Participants eligible for the study are patients with breast cancer, planned for mastectomy, who wishes IBR with implants. Each participant is individually randomized to either be reconstructed using implants with total submuscular coverage (A) or reconstruction with ADM and partial muscle coverage (B).

Method of assigning patients to treatment groups:

After signing and dating the informed consent the patient is entered into the study. If all inclusion and none of the exclusion criteria are full filled, the patient will be randomized to group A or group B.

TREATMENT/ INTERVENTION The decision and treatment plan advocating mastectomy is based on multi disciplinary conference (MDT), and the diagnosis of invasive or pre-invasive (in situ) breast cancer is made on triple assessment. If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.

Randomization at enrollment is made with regard to the use of ADM or not, so both expander and direct-to-implant techniques will be utilized in both groups, depending on the quality of skin flaps at time of surgery.

RANDOMIZATION TYPE Patients will be allocated to treatment according to permuted block technique. The actual randomization will be performed using computer based system located at Regional Cancer Center (RCC) within Karolinska Institutet. In this system inclusion and exclusion criteria will be automatically checked before patients are randomized to treatment. The randomization process will be stratified for the participating units.

STATISTICAL METHODS The main endpoint to be analyzed is the proportion of unplanned reoperations after the initial breast reconstruction. The difference in proportions between the two groups will be presented as a difference in proportion together with a 95% confidence interval. Differences will be tested using Fishers Exact Test. Logistic regression will be used to take into account possible confounding factors.

STUDY MANAGEMENT Data recording: The investigators will ensure that all data from patient visits are entered promptly in ink, in the case report forms (CRF). The principal investigator must sign the final CRF page to attest to the accuracy and completeness of the data. The data from the CRFs are then transferred to a database.

Monitoring and audit: At periods not exceeding 3 months, centers will be contacted to discuss the progress of the trial, with the purpose to verify CRF data against source records for accuracy of data recording and collection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast reconstruction with ADM

Implant based Breast Reconstruction with ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implants. Patients in group B with ADM and partial submuscular coverage.

Group Type EXPERIMENTAL

Reconstruction with ADM.

Intervention Type PROCEDURE

If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.

Skin or nipple sparing mastectomy

Intervention Type PROCEDURE

Mastectomy for invasive or pre-invasive breast cancer

Reconstruction with implant

Intervention Type PROCEDURE

Immediate breast reconstruction with implant

Partial submuscular coverage

Intervention Type PROCEDURE

Implant based breast reconstruction with partial submuscular coverage

Breast reconstruction without ADM

Breast reconstruction without ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implant. Patients in group B will be reconstructed with implant and total submuscular coverage.

Group Type ACTIVE_COMPARATOR

Skin or nipple sparing mastectomy

Intervention Type PROCEDURE

Mastectomy for invasive or pre-invasive breast cancer

Reconstruction with implant

Intervention Type PROCEDURE

Immediate breast reconstruction with implant

Total submuscular coverage

Intervention Type PROCEDURE

Implant based breast reconstruction with total submuscular coverage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Reconstruction with ADM.

If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.

Intervention Type PROCEDURE

Skin or nipple sparing mastectomy

Mastectomy for invasive or pre-invasive breast cancer

Intervention Type PROCEDURE

Reconstruction with implant

Immediate breast reconstruction with implant

Intervention Type PROCEDURE

Total submuscular coverage

Implant based breast reconstruction with total submuscular coverage

Intervention Type PROCEDURE

Partial submuscular coverage

Implant based breast reconstruction with partial submuscular coverage

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Strattice ADM Implant Immediate breast reconstruction Acellular dermal matrix Mastectomy Breast cancer Direct-to-implant Expander Breast reconstruction Mastectomy Skin sparing mastectomy Nipple sparing mastectomy Acellular dermal matrix Immediate breast reconstruction ADM Breast cancer Strattice Implant Implant Mastectomy Acellular dermal matrix Direct-to-implant Immediate breast reconstruction ADM Strattice Breast cancer

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with invasive or pre-invasive (in situ) breast cancer, planned for immediate breast reconstruction post-skin sparing or nipple sparing mastectomy (unilateral or bilateral)
* Patient agrees to participate in study and to sign an informed consent form
* Able and willing to return for all scheduled and required study visits

Exclusion Criteria

* Is a smoker (patient having quit at least 4 weeks prior surgery can be included)
* BMI \<18 or \> 30
* Previous radiation therapy to the region at any time
* Insulin-dependent diabetes or any immune deficiency requiring immunosuppressant use such as cortisone or biological therapies
* Predicted implant size \<200 or \>600 ml per investigator assessment
* Allergy to porcine
* Pregnancy or lactating
* Current enrollment or plans to enroll in another clinical trial unless a retrospective study
* Neoadjuvant treatment with chemotherapy

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No